

Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-May-2020
 Document Type: USP Monographs
 DocId: GUID-A5639E2E-13B3-48B4-9C13-671BAC2ECBAA_3_en-US
 DOI: https://doi.org/10.31003/USPNF_M31690_03_01
 DOI Ref: 30tbq

© 2025 USPC
 Do not distribute

Ethosuximide Oral Solution

DEFINITION

Ethosuximide Oral Solution contains NLT 90.0% and NMT 105.0% of the labeled amount of ethosuximide ($C_7H_{11}NO_2$).

IDENTIFICATION

Change to read:

- **A.** ▲ **SPECTROSCOPIC IDENTIFICATION TESTS** (197), **Infrared Spectroscopy: 197S** ▲ (CN 1-May-2020)

Standard solution: 30.0 mg/mL of [USP Ethosuximide RS](#) in [chloroform](#)

Sample solution: Nominally 30 mg/mL of ethosuximide in [chloroform](#) prepared as follows. Transfer the equivalent of about 150 mg of ethosuximide from Oral Solution to a 125-mL separatory funnel, add 50 mL of [ether](#), and shake well. Allow the layers to separate, and retain the ether layer. Wash the ether layer with three 10-mL portions of [water](#). Transfer the ether layer to a suitable beaker, add 5 g of [anhydrous sodium sulfate](#), and swirl. Filter the mixture into a 50-mL volumetric flask through a small pledget of cotton that has been previously washed with [ether](#). Evaporate to dryness. Dissolve the residue in 5 mL of [chloroform](#).

Wavelength range: 3000–1650 cm^{-1}

Analysis

Samples: *Standard solution* and *Sample solution*

Acceptance criteria: Meets the requirements

- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

Change to read:

PROCEDURE

Mobile phase: [Acetonitrile](#) and [water](#) (12.5:87.5). To each liter, add 1.0 mL of [glacial acetic acid](#).

System suitability solution: 0.062 mg/mL of [USP Ethosuximide RS](#) and 0.064 mg/mL of [2-ethyl-2-methylsuccinic acid](#) in *Mobile phase*

Standard solution: 0.062 mg/mL of [USP Ethosuximide RS](#) in *Mobile phase*

Sample solution: Nominally 0.062 mg/mL of ethosuximide from Oral Solution in *Mobile phase* prepared as follows. Transfer a volume of Oral Solution, equivalent to 250 mg of ethosuximide, to a 100-mL volumetric flask. Dilute with *Mobile phase* to volume. Transfer 5.0 mL of this solution to a 200-mL volumetric flask and dilute with *Mobile phase* to volume.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 225 nm

Column: 3.9-mm × 15-cm; ▲4- μm ▲ (USP 1-May-2019) packing L1

Flow rate: 1 mL/min

Injection volume: 10 μL

▲**Run time:** NLT 2 times the retention time of ethosuximide ▲ (USP 1-May-2019)

System suitability

Sample: *System suitability solution*

▲[NOTE—The relative retention times for ethosuximide and 2-ethyl-2-methylsuccinic acid are 1.0 and 1.3, respectively.] ▲ (USP 1-May-2019)

Suitability requirements

Resolution: NLT 3.5 between ethosuximide and 2-ethyl-2-methylsuccinic acid

Tailing factor: NMT 1.5

Relative standard deviation: NMT ▲1.0% ▲ (USP 1-May-2019) for ethosuximide and NMT 5.0% for 2-ethyl-2-methylsuccinic acid

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of ethosuximide ($C_7H_{11}NO_2$) in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Ethosuximide RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of ethosuximide in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–105.0%

IMPURITIES

• **LIMIT OF 2-ETHYL-2-METHYLSUCCINIC ACID**

Mobile phase, System suitability solution, Chromatographic system, and System suitability: Proceed as directed in the Assay.

Standard solution: 0.05 mg/mL of [2-ethyl-2-methylsuccinic acid](#) in *Mobile phase*

Sample solution: Nominally 2.5 mg/mL of ethosuximide from Oral Solution in *Mobile phase* prepared as follows. Using a “to contain” pipet, transfer a volume of Oral Solution, equivalent to 250 mg of ethosuximide, to a 100-mL volumetric flask. Rinse the pipet several times with *Mobile phase*, and dilute with *Mobile phase* to volume.

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of 2-ethyl-2-methylsuccinic acid in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of 2-ethyl-2-methylsuccinic acid from the *Sample solution*

r_S = peak response of 2-ethyl-2-methylsuccinic acid from the *Standard solution*

C_S = concentration of 2-ethyl-2-methylsuccinic acid in the *Standard solution* (mg/mL)

C_U = nominal concentration of ethosuximide in the *Sample solution* (mg/mL)

Acceptance criteria: NMT 2.0%

SPECIFIC TESTS

• **pH (791):** 4.5–5.8

ADDITIONAL REQUIREMENTS

Change to read:

• **PACKAGING AND STORAGE:** Preserve in tight containers. ▲Store at controlled room temperature. Protect from freezing and light.▲ (USP 1-May-2019)

• **USP REFERENCE STANDARDS (11).**
[USP Ethosuximide RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ETHOSUXIMIDE ORAL SOLUTION	Documentary Standards Support	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(1)

Current DocID: [GUID-A5639E2E-13B3-48B4-9C13-671BAC2ECBAA_3_en-US](#)

DOI: https://doi.org/10.31003/USPNF_M31690_03_01

DOI ref: [30tbq](#)